Concepedia
Statistics
Publications
30
Citations
2K
H-Index
22
Active since
1998
Affiliations
AstraZeneca (United States)(Current)
AstraZeneca (United Kingdom)
Northeastern University
Novartis (Switzerland)
Novartis (United States)
Eric T. Gangl is an author at AstraZeneca (United States) specializing in pharmacology, pharmacy, and drug discovery.
Publications per year
1998–2025
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
Adriana E. Tron, Matthew A. Belmonte, Ammar Adam et al. · Nature Communications · 2018 · 486 citations · Full text
Medicine, Medicinal Chemistry, Pharmacology +17
Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir.
T. Koudriakova, Eugenia Iatsimirskaia, Ilya Utkin et al. · PubMed · 1998 · 244 citations
Medicine, Pharmacokinetics, Pharmacology +17
Reduction of Signal Suppression Effects in ESI-MS Using a Nanosplitting Device
Eric T. Gangl, Meg Annan, Neil Spooner et al. · Analytical Chemistry · 2001 · 181 citations
Pharmacy, Pharmaceutical Analysis, Analytical Chemistry +13
Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist
James S. Scott, Amber Balazs, Bernard Barlaam et al. · Journal of Medicinal Chemistry · 2020 · 111 citations · Full text
Pharmacy, Medicinal Chemistry, Pharmacology +17
Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy
Claire Patterson, Srividya B. Balachander, Iain Grant et al. · Communications Biology · 2021 · 95 citations · Full text
Pharmacy, Medicinal Chemistry, Pharmacology +14
1–5 of 30